ANDA 206553, held by Tp Anda Holdings. Cyproheptadine Hydrochloride.
As of Nov 16, 2026, ANDA 206553 (Cyproheptadine Hydrochloride), held by Tp Anda Holdings, was first approved by FDA on Nov 29, 2016, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 29, 2016 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Cyproheptadine Hydrochloride4MG · tablet;oral | Cyproheptadine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters